Search
Rimiducid
go.drugbank.com/drugs/DB04974InvestigationalIt was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function.
Piboserod
go.drugbank.com/drugs/DB04873InvestigationalPiboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.
Davunetide
go.drugbank.com/drugs/DB12613InvestigationalDavunetide is derived from a naturally occurring neuroprotective brain protein known as activity dependent neuroprotective protein. … Davunetide has been used in trials studying the treatment of Progressive Nonfluent Aphasia, Progressive Supranuclear Palsy, Predicted Tauopathies, Including, Corticobasal Degeneration Syndrome, and Frontotemporal
MLN8054
go.drugbank.com/drugs/DB13061InvestigationalMLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.
Palifosfamide
go.drugbank.com/drugs/DB05668InvestigationalIfosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.
L523S
go.drugbank.com/drugs/DB06498Investigational[A175909] It has been investigated as a lung cancer vaccine. … According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S)
Recombinant Super-Compound Interferon
go.drugbank.com/drugs/DB15752InvestigationalThis interferon has antiviral and antitumor activity.
CLX-0921
go.drugbank.com/drugs/DB05854ExperimentalCLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. This substance targets the protein peroxisome proliferator-activated receptor gamma.
Asciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigational[L39005] It has also shown benefit in Ph+ CML with the T315I mutation, which produces a mutant BCR-ABL1 which is typically treatment-resistant as compared to wild-type BCR-ABL1. … [A241065] Asciminib is unique in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and locking it into an inactive conformation.
Vibrio cholerae CVD 103-HgR strain live antigen
go.drugbank.com/drugs/DB14443ApprovedInvestigational[A244494] Vaxchora was later approved by the European Commission in April 2020.[L39729] It is indicated for individuals aged two years and older.[L12801]